What's Going On With Fulcrum Therapeutics Stock Tuesday?

Fulcrum's new sickle cell trial data show higher hemoglobin levels and no serious safety concerns in sickle cell disease ...
Nasdaq

Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?

Fulcrum Therapeutics FULC, a clinical-stage company, is expected to report third-quarter 2024 results early next month. The Zacks Consensus Estimate for the to-be-reported quarter’s loss is pinned at ...
newscase

Fulcrum Therapeutics Shares Surge on Promising Clinical Trial Data and Strong Financial Runway

Fulcrum Therapeutics reports promising Phase 1b data for pociredir in sickle cell disease and a strong cash position to fund development into 2029, boosting investor confidence.

Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically ...
Seeking Alpha

Fulcrum's Balance: Between Promise And Uncertainty

Fulcrum Therapeutics focuses on rare genetic diseases with losmapimod in Phase 3 trial; stock is down 56% since February. Fulcrum's financial health is strong with $278.2M in cash; monthly cash burn ...